SHARE
ASCO GU 2021: Clinical Outcomes of Patients With mCRPC Receiving Radium-223 Early Versus Late in the Treatment Sequence
Published 11 February 2021
(UroToday.com) Data from the landmark ALSYMPCA trial
1 found that the targeted alpha therapy Radium-223 prolonged overall survival in men with metastatic castration-resistant prostate cancer (mCRPC).
1 However, there is little data to guide clinicians as to the appropriate sequence for use of Radium-223 in men with mCRPC with regards to other life-prolonging therapies. At the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU), Dr. Lawrence Mbuagbaw and colleagues presented results of their real-world study evaluating clinical outcomes of patients when Radium-223 was used early (second-line) or late (third or later lines) among men with mCRPC.
Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Anne Schuckman discussing which patients with high-risk non-muscle-invasive bladder cancer may benefit from radical cystectomy. Dr. Shuckman notes that more than 70% of all newly diagnosed bladder cancers are non-muscle-invasive, including Ta (70%), T1 (20%), and CIS (10%). The natural history of non-muscle-invasive bladder cancer stratified by low-grade Ta, high-grade Ta and high-grade T1 is depicted in the following table:
Data from Moschini and colleagues suggest that whether T2 disease is de novo or progressive is prognostically important.
Published 16 February 2021
(UroToday.com) The optimizing personalized management of non-muscle-invasive bladder cancer session at the 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU) included a presentation from Dr. Angela Smith discussing deintensification of management of low-risk non-muscle-invasive bladder cancer. Dr. Smith notes that it is important to distinguish between low risk versus low grade non-muscle-invasive bladder cancer. According to the AUA risk stratification for non-muscle-invasive bladder cancer low risk disease is either a low-grade solitary Ta 3 cm tumor or PUNLMP. Conversely, there are several instances where low grade tumors are intermediate risk, including low grade Ta tumors that recur within 1 year of resection, solitary low grade Ta tumors 3cm, and multifocal low grade Ta tumors.
Published 14 February 2021
(UroToday.com) The 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium included a Best of Journals: Renal Cell Carcinoma Session with Dr. Saby George from the Roswell Park Cancer Institute presenting impactful papers from the medical oncology perspective.
The first paper discussed by Dr. George was Motzer et al. s “Nivolumab Versus Everolimus in Patients with Advanced Renal Cell Carcinoma: Updated Results with Long-Term Follow-Up of the Randomized, Open-Label, Phase 3 CheckMate 025 Trial” was published in
Cancer.
1 CheckMate 025 previously showed superior efficacy for nivolumab over everolimus in patients with advanced renal cell carcinoma along with improved safety and tolerability.
Published 14 February 2021
(UroToday.com) Members of the forkhead transcription factor (FOX) family are important mediators of embryonic development and are known to be altered in a variety of cancers. However, to date, the functional role of
FOXF1 in bladder tumorigenesis and progression has not been clearly characterized. At the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Anirban Mitra and colleagues from the MD Anderson Cancer Center reported results of their study investigating the clinical implications of differential
FOXF1 expression in bladder cancer, and potential mechanisms by which its alteration can lead to tumor metastasis.
For this study, whole-genome expression profiling was performed on paired primary tumors and nodal metastases from a radical cystectomy discovery cohort using Illumina HT12 v3-4 BeadChip arrays to identify